Portal de investigación
Clinical performance of tumor-informed versus tumor-agnostic ctDNA assays for colorectal cancer recurrence: A systematic review and diagnostic accuracy meta-analysis
Fecha de publicación:
Fecha Ahead of Print:
Autores de INCLIVA
Participantes ajenos a INCLIVA
- Martínez-Picó F
- Pappas L
- Parikh A
Grupos y Plataformas de I+D+i
Abstract
In patients with early-stage colorectal cancer (CRC), circulating tumor DNA (ctDNA) testing is increasingly used to detect minimal residual disease (MRD) after curative-intent surgery. This information can guide decisions on adjuvant chemotherapy and surveillance. Two main approaches exist, tumor-informed (TI) and tumor-agnostic (TA), however, their diagnostic accuracy in clinical practice remains unclear. We conducted a bivariate diagnostic meta-analysis to compare sensitivity and specificity of TI versus TA ctDNA assays for detecting recurrence in patients with resected CRC. Subgroup analyses were performed based on landmark versus serial sampling strategies. In the serial-sampling setting, TI assays demonstrated markedly higher sensitivity than TA assays (0.88 vs. 0.59; p = 0.001), with no significant differences in false-positive rates. The landmark analyses did not show statistically significant differences between approaches. The results underscore the importance of sampling strategy when selecting a ctDNA test. When longitudinal monitoring is feasible, TI assays provide the most reliable detection of recurrence. This meta-analysis supports tailoring ctDNA testing to the clinical context, prioritizing TI approaches for serial surveillance to better guide adjuvant decision-making and improve patient outcomes.
Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 0305-7372, 1532-1967
- Tipo:
- Review
- Páginas:
- 103066-103066
- PubMed:
- 41401645
CANCER TREATMENT REVIEWS ELSEVIER SCI LTD
Documentos
- No hay documentos
Filiaciones
Keywords
- Colorectal cancer; Circulating tumor DNA; Tumor-informed; Tumor-agnostic; Sensitivity; False positive rate; Diagnostic accuracy
Financiación
Proyectos y Estudios Clínicos
CONTRATOS PREDOCTORALES DE FORMACIÓN EN INVESTIGACIÓN EN SALUD
Investigador/a Principal BLANCA GARCÍA MICÓ
FI22/00267 . INSTITUTO SALUD CARLOS III . 2023
Descifrando la heterogeneidad tumoral mediante la biopsia líquida para abordar la enfermedad mínima residual en el cáncer de colon localizado.
Investigador/a Principal BELÉN MARTÍNEZ CASTEDO
FPU21/00373 . MINISTERIO EDUCACION, CULTURA Y DEPORTE . 2022
Enfoque integral de la enfermedad micrometastásica hepática en cáncer colorrectal: caracterización multiómica de metástasis, respuesta inmune y abordaje de la enfermedad residual.
Investigador/a Principal NOELIA TARAZONA LLAVERO
PI24/00103 . INSTITUTO SALUD CARLOS III . 2025
Comprehensive multi-omic and ctDNA analysis of lung cancer evolution and therapy resistance in TRACERx.
Investigador/a Principal JORGE MARTÍN ARANA
CIAPOS/2024/055 . CONSELLERIA EDUCACION/INNOVACION,UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL/EMPLEO . 2025
Cita
Clinical performance of tumor-informed versus tumor-agnostic ctDNA assays for colorectal cancer recurrence: A systematic review and diagnostic accuracy meta-analysis. Camblor,DG, Martínez Castedo,B, Martín Arana,J, Gimeno Valiente,F, García Micó,B, Martínez Picó,F, Seguí,V et al. CANCER TREATMENT REVIEWS. 2026 enero 01. 142103066-103066. DOI:10.1016/j.ctrv.2025.103066. PMID:41401645.
